Coronary Disease
Showing 51 - 75 of 666
Multi-Ethnic Study of Atherosclerosis (MESA)
Active, not recruiting
- Atherosclerosis
- +10 more
- (no location specified)
May 3, 2022
Atherosclerosis, Inflammatory Response, Coronary Disease Trial in São paulo (Colchicine)
Recruiting
- Atherosclerosis
- +2 more
-
São paulo, Sao Paulo, BrazilHeart Institute - University of São Paulo
May 3, 2022
Coronary Stenosis, Coronary Disease, Non-ST Elevated Myocardial Infarction Trial (IoNIR Ridaforolimus-Eluting Coronary Stent
Not yet recruiting
- Coronary Stenosis
- +3 more
- IoNIR Ridaforolimus-Eluting Coronary Stent System
- (no location specified)
May 3, 2022
Coronary Disease, Coronary Artery Disease, Calcific Coronary Arteriosclerosis Trial in Lucerne (OPN™ NCB Super High Pressure PCI
Not yet recruiting
- Coronary Disease
- +4 more
- OPN™ NCB Super High Pressure PCI Balloon
- Shockwave™ C2 IVL Catheter
-
Lucerne, SwitzerlandLuzerner Heart Centre
Apr 19, 2022
Coronary Disease, Coronary Artery Disease, Coronary Restenosis Trial in Lucerne (Sirolimus Eluting Balloon)
Recruiting
- Coronary Disease
- +9 more
- Sirolimus Eluting Balloon
-
Lucerne, SwitzerlandLuzerner Heart Centre
Mar 31, 2022
Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Completed
- Coronary Artery Disease
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 7, 2022
EluNIR Ridaforolimus Eluting Coronary Stent System In Coronary
Completed
- Coronary Stenosis
- +3 more
- EluNIR Ridaforolimus Eluting Coronary Stent System
-
Be'er Sheva, Israel
- +8 more
Apr 5, 2022
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome Trial in Harbin (immediate stenting group(one-step
Recruiting
- Coronary Artery Disease
- +9 more
- immediate stenting group(one-step strategy)
- deferred stenting group (two-step strategy)
-
Harbin, Heilongjiang, ChinaThe 2nd Affiliated Hospital of Harbin Medical University
Mar 31, 2022
Coronary Disease Trial in Zhengzhou (remote ischemic preconditioning (RIPC))
Recruiting
- Coronary Disease
- remote ischemic preconditioning （RIPC）
-
Zhengzhou, Henan, ChinaFuwai central China cardiovascular Hospital
Mar 29, 2022
Various Configurations of Different Arterial Grafts in Total
Not yet recruiting
- Coronary Syndrome
- +2 more
- coronary artery bypass grafting surgery
- (no location specified)
Mar 18, 2022
Acute Coronary Syndromes in Transitional Countries
Recruiting
- Acute Coronary Syndrome
- +3 more
-
Bologna, Emilia Romagna, ItalyUniversity of Bologna
Mar 10, 2022
Coronary Disease Trial in Beijing (Paclitaxel DCB, DES)
Completed
- Coronary Disease
- Paclitaxel DCB
- DES
-
Beijing, Beijing, ChinaBeijing Hospital
Mar 21, 2022
Coronary Disease Trial in Beijing (Paclitaxel DCB)
Recruiting
- Coronary Disease
- Paclitaxel DCB
-
Beijing, Beijing, ChinaBeijing Hospital
Mar 21, 2022
Cardiac Output, Low, Coronary Disease Trial in Sao Paulo (Liberal dobutamine protocol, Restrictive dobutamine protocol)
Completed
- Cardiac Output, Low
- Coronary Disease
- Liberal dobutamine protocol
- Restrictive dobutamine protocol
-
Sao Paulo, SP, BrazilHeart Institute
Mar 14, 2022
Nurses' Health Study (Cardiovascular Component)
Active, not recruiting
- Cardiovascular Diseases
- +9 more
- (no location specified)
Mar 1, 2022
Coronary Disease, Stroke, Chronic Kidney Disease Trial in Calgary (Copayment Elimination, Personalized Education)
Completed
- Coronary Disease
- +6 more
- Copayment Elimination
- Personalized Education
-
Calgary, Alberta, CanadaUniversity of Calgary
Mar 2, 2022
Coronary Disease, Coronary Stenoses Trial in Korea, Republic of (quantitative coronary angiography guided coronary intervention
Active, not recruiting
- Coronary Disease
- Coronary Stenoses
- quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent
- intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent
-
Anam, Korea, Republic of
- +8 more
Mar 1, 2022
Heart Failure, Cardiomyopathy, Dilated, Coronary Disease Trial in Pessac (Resynchronization using a transeptal approach,
Completed
- Heart Failure
- +2 more
- Resynchronization using a transeptal approach
- Resynchronization using a coronary sinus approach
-
Pessac, FranceCardiologic Hospital Haut l'évêque
Feb 8, 2022
Hypercholesterolemia, Coronary Disease Trial (Ezetimibe/Simvastatin 10/20 mg, simvastatin 40 mg)
Completed
- Hypercholesterolemia
- Coronary Disease
- Ezetimibe/Simvastatin 10/20 mg
- simvastatin 40 mg
- (no location specified)
Feb 7, 2022
Coronary Disease Trial (MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27
Completed
- Coronary Disease
- MK0653, ezetimibe / Duration of Treatment: 27 Weeks
- +2 more
- (no location specified)
Feb 7, 2022
Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease Trial (MK0653A , ezetimibe (+) simvastatin, Comparator:
Completed
- Hypercholesterolemia
- +2 more
- MK0653A , ezetimibe (+) simvastatin
- +2 more
- (no location specified)
Feb 3, 2022
Mediators of Atherosclerosis in South Asians Living in America
Recruiting
- Atherosclerosis
- +4 more
-
San Francisco, California
- +2 more
Jan 29, 2022
University of North Carolina Alumni Heart Study
Active, not recruiting
- Cardiovascular Diseases
- +3 more
- There is no intervention
-
Durham, North CarolinaDuke University, Behavioral Medicine Research Center
Jan 28, 2022
Hypercholesterolemia, Diabetes, Type 2, Coronary Disease Trial (Ezetimibe 10 mg, Simvastatin 20 mg, Ezetimibe Placebo)
Completed
- Hypercholesterolemia
- +2 more
- Ezetimibe 10 mg
- +3 more
- (no location specified)
Feb 7, 2022